Table 4 Reduced-intensity regimens for leukemia/myelodysplastic syndrome
Conditioning regimen | Drug | Dose (total) | Schedule(d) | Donor type |
|---|---|---|---|---|
International regimen | ||||
Flu/Mel | Flu | 150 mg/m2 | − 7 ~ − 3 | Allo-HSCT |
Mel | 140 mg/m2 | − 2, − 1 | ||
Flu/Bu | Flu | 150 mg/m2 | − 9 ~ − 5 | Allo-HSCT |
Bu | 8~ 10 mg/kg (po) | − 6 ~ − 4 | ||
Flu/Cy | Flu | 150 mg/m2 | − 7 ~ − 3 | Allo-HSCT |
Cy | 140 mg/m2 | − 2, − 1 | ||
Flu/Bu/TT | Flu | 150 mg/m2 | − 7 ~ − 5 | Allo-HSCT |
Bu | 8 mg/kg (po) | − 6 ~ − 4 | ||
Thiotepa | 5 mg/kg | − 3 | ||
TBI/Cy/ATG | TBI | 4 Gy | − 5 | Flu+Ara-C+AMSA, followed by allo-HSCT |
Cy | 120 mg/kg | − 4, − 3 | ||
ATG | ||||
Modified regimen(PUPH) | ||||
RIC-mBuCy | Hu | 80 mg/kg (divided in two) | − 10 | HLA-matched sibling HSCT |
Ara-C | 2 g/m2 (CI) | − 9 | ||
Bu | 4.8 mg/kg (iv) | − 10, − 9 | ||
Cy | 2.0 g/m2 | − 5, − 4 | ||
MeCCNU | 250 mg/m2 (po) | − 3 | ||
ATG | 10 mg/m2 | − 5 ~ − 2 | ||
or ATG-F | 40 mg/kg | − 5 ~ − 2 | ||
RIC-BuFlu | Hu | 80 mg/kg (divided in two) | − 10 | HLA-matched sibling HSCT |
Ara-C | 2 g/m2 (CI) | − 9 | ||
Bu | 9.6 mg/kg (iv) | − 8 ~ − 6 | ||
Flu | 150 mg/m2 | − 6 ~ − 2 | ||
MeCCNU | 250 mg/m2 | − 3 | ||
RIC-mBuFluATG | Ara-C | 8 g/m2 (CI) | − 10/− 9 | HID-HSCT |
Bu | 9.6 mg/kg (iv) | − 8 ~ − 6 | ||
Flu | 150 mg/m2 | − 6 ~ − 2 | ||
MeCCNU | 250 mg/m2 | − 3 | ||
ATG | 10 mg/kg | − 5 ~ − 2 | ||
or ATG-F | 40 mg/kg | − 5 ~ − 2 | ||
RIC-mBuCyFlu+ATG | Ara-C | 8 g/m2 (CI) | − 10/− 9 | HID-HSCT |
Bu | 9.6 mg/kg (iv) | − 8 ~ − 6 | ||
Flu | 150 mg/m2 | − 6 ~ − 2 | ||
Cy | 2.0 g/m2 | − 5, − 4 | ||
MeCCNU | 250 mg/m2 | − 3 | ||
ATG | 10 mg/kg | − 5 ~ − 2 | ||
or ATG-F | 40 mg/kg | − 5 ~ − 2 | ||